Dose selection in phase I studies: Why we should always go for the most effective

Journal of Clinical Oncology

Volumn 26, Issue 21, 2008, Pages 3650-3652

  Haines, Ian E ^a  

^a CABRINI INSTITUTE   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; DOCETAXEL; DRUG METABOLITE; EVEROLIMUS; GEMCITABINE; IMATINIB; IRINOTECAN; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; OXALIPLATIN; PACLITAXEL; SORAFENIB; SU 12662; SUNITINIB; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT;

ANEMIA; AREA UNDER THE CURVE; BLEEDING; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CANCER THERAPY; CLINICAL TRIAL; DIARRHEA; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG MEGADOSE; DYSPNEA; EDEMA; FATIGUE; FOLLOW UP; GASTROINTESTINAL STROMAL TUMOR; HUMAN; KIDNEY CANCER; LETHARGY; LETTER; LOW DRUG DOSE; MAXIMUM TOLERATED DOSE; METASTASIS; NAUSEA; PRIORITY JOURNAL; QUALITY OF LIFE; TREATMENT OUTCOME; TREATMENT RESPONSE; METHODOLOGY; NEOPLASM; NOTE; PHASE 1 CLINICAL TRIAL;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; MAXIMUM TOLERATED DOSE; NEOPLASMS;

EID: 49049122081     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.6719     Document Type: Letter

References (23)

1. Sleijfer S, Wiemer E: Dose selection in phase I studies: Why we should always go for the top. J Clin Oncol 26:1576-1578, 2008
2. Haines IE: A positive step forward, but more needed to maximize cost benefits of new-generation cancer therapies. J Clin Oncol 25:31e-32e, 2007
3. Haines IE, Miklos GL: Paclitaxel plus bevacizumab for metastatic breast cancer. N Engl J Med 358:1637-1638, 2008
4. Pollack A: Cutting dosage of costly drug spurs a debate. New York Times. http://www.nytimes.com/2008/03/16/business/16gaucher.html
5. Atkins MB, Hidalgo M, Stadler WM, et al: Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909-918, 2004
6. Tanaka C, O'Reilly T, Kovarik JM, et al: Identifying optimal biologic doses of everolimus (RAD001) in cancer patients based on the modeling of preclinical and clinical pharmacokinetic and pharmacodynamic data. J Clin Oncol 26:1596-1602, 2008
7. O'Donnell A, Faivre S, Burris HA III, et al: A phase I pharmacokinetic and pharmacodynamic study of the oral mTOR inhibitor everolimus (RAD001) in patients with advanced solid tumors. J Clin Oncol 26:1588-1595, 2008
8. Tabernero J, Rojo F, Calvo E, et al: Dose- and schedule-dependent inhibition of the mTOR pathway with everolimus: A phase I tumor pharmacodynamic study in patients with solid tumors. J Clin Oncol 26:1603-1610, 2008
9. Van Glabbeke M, Owzar K, Rankin C, et al: Comparison of two doses of imatinib for the treatment of gastrointestinal stromal tumors (GIST): A meta-analysis based on 1640 patients. J Clin Oncol 25:546s, 2007 (suppl; abstr 10004)
10. Choi H, Macapinlac H, Burgess M, et al: Correlation of computerized tomography (CT) and positron emission tomography (PET) in patients with metastatic GIST treated at a single institution with imatinib mesylate. Proc Am Soc Clin Oncol 22:819, 2003 (abstr 1359)
11. Choi H, Charnsangavej C, Faria S, et al: Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: Proposal of new computed tomography response criteria. J Clin Oncol 25:1753-1759, 2007
12. Benjamin RS, Choi H, Macapinlac HA, et al: We should desist using RECIST, at least in GIST. J Clin Oncol 25:1760-1764, 2007
13. Verweij J, Casali PG, Zalcberg J, et al: Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: Randomised trial. Lancet 364:1127-1134, 2004
14. Casali PG, Verweij J, Kotasek D, et al: Imatinib mesylate in advanced gastrointestinal stromal tumors (GIST): Survival analysis of the Intergroup EORTC/ISG/AGITG randomized trial in 946 patients. Eur J Cancer 3:201, 2005 (suppl; abstr 711)
15. Blanke CD, Rankin C, Demetri GD, et al: Phase III randomized, Intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033. J Clin Oncol 26:626-632, 2008
16. Zalcberg JR, Verweij J, Casali PG, et al: Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg. Eur J Cancer 41:1751-1757, 2005
17. Amato RJ, Harris P, Dalton M, et al: A phase II trial of intra-patient dose-escalated sorafenib in patients (pts) with metastatic renal cell cancer (MRCC). J Clin Oncol 25:241s, 2007 (suppl; abstr 5027)
18. Houk BE, Bello CL, Michaelson MD, et al: Exposure-response of sunitinib in metastatic renal cell carcinoma (mRCC): A population pharmacokinetic/ pharmacodynamic (PKPD) approach. J Clin Oncol 25:241s, 2007 (suppl; abstr 5027)
19. Gonzalez-Angulo AM, Hortobagyi GN: Optimal schedule of paclitaxel: Weekly is better. J Clin Oncol 26:1585-1587, 2008
20. Traina TA, Theodoulou M, Feigin K, et al: Phase I study of a novel capecitabine schedule based upon the Norton-Simon mathematical model in patients with metastatic breast cancer. J Clin Oncol 26:1797-1802, 2008
21. Twelves CJ: Defining the optimal schedule of drug administration: Art or science? J Clin Oncol 26:1781-1782, 2008
22. Kolata G: Co-payments soar for drugs with high prices. New York Times. http://www.nytimes.com/2008/04/14/us/14drug.html
23. Mongan JJ, Ferris TG, Lee TH: Options for slowing the growth of health care costs. N Engl J Med 358:1509-1514, 2008